



Express Mail No.: EV 452 776 507 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava *et al.*

Confirmation No.: 1804

Serial No.: 09/668,724.

Art Unit: 1642

Filed: September 22, 2000

Examiner: Judy L. Tidwell

For: ALPHA (2) MACROGLOBULIN
RECEPTOR AS A HEAT SHOCK
PROTEIN RECEPTOR AND USES
THEREOF

Attorney Docket No: 8449-128-999

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97**

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants respectfully direct the Examiner's attention to the references **A08-A13, B15 and C89-C114** listed on the attached List of References Cited by Applicant. Copies of references **B15 and C89-C114** are submitted herewith.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application. Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.


06/26/2006 MAHMED1 00000047 09668724

01 FC:1806 180.00 DA

Pursuant to 37 C.F.R. §1.97(b), since it is believed that this information disclosure statement is being filed after the mailing date of a first Office Action on the merits, a fee of \$180 is believed to be due in connection herewith. Please charge the required fee to Jones Day deposit account no. 50-3013.

Respectfully submitted,

Date June 21, 2006

 32,605
Adriane M. Antler (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosure



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

8449-128-999

APPLICATION NO.

09/668,724

APPLICANT

Pramod K. Srivastava, et al.

FILING DATE

September 22, 2000

ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A08	5,112,298	5/12/1992	Prince et al.	
	A09	5,554,293	9/10/1996	Uhoch	
	A10	5,637,082	6/10/1997	Pages et al.	
	A11	5,846,928	12/8/1998	Kishida	
	A12	6,027,731	2/22/2000	Pauza	
	A13	6,033,561	3/7/2000	Schoendorfer	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B15	WO 0038760	7/6/2000	Occulogix Corp		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C89	Binder et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	
	C90	Binder et al., 2001, "Adjuvanticity of alpha 2-macroglobulin, an independent ligand for the heat shock protein receptor CD91," J. Immunol. 166(8):4968-4972	
	C91	Binder et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
	C92	Bosch et al., 1999, "State of the art of therapeutic apheresis in Europe," Ther. Apher. 3(3):197-198	
	C93	D'Andrea, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," 64(3):458-463	
	C94	Epplen et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-352.	
	C95	Fay et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)," Blood 54: 747-749	
	C96	Herz et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor," J.Biol.Chem. 266(31):21232-21238	
	C97	Kimber et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation," Biochem. Cell Biol. 2002;80(1):103-107	
	C98	Kornfeld et al., 1980, "Plasmapheresis in Myasthenia Gravis," Plasma Therapy 2(3): 127-133	
	C99	McKee and Collins, 1974, "Intravascular Leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia," Medicine 53: 463-478	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYJD-1626626v1



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

8449-128-999

APPLICATION NO.

09/668,724

APPLICANT

Pramod K. Srivastava, et al.

FILING DATE

September 22, 2000

ART UNIT

1642

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C100	Millward and Hoeltge, 1982, "The Historical Development of Automated Hemapheresis," J. of Clin. Apheresis 1: 25-32	
	C101	Moestrup et al., 1991, "Analysis of Ligand Recognition by the purified alpha-2M- macroglobulin receptor (low density lipoprotein receptor-related protein)," J. Biol. Chem. 266(21):14011-14017	
	C102	Pineda et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 1994 Sep;69(9):893-894	
	C103	Report of the AMA Panel on Therapeutic Plasmapheresis, "Current Status of Therapeutic Plasmapheresis and Related Techniques," J. of the Council on Scientific Affairs, Amer. Med. Assoc. Dec. 1984	
	C104	Singh, 1997, "Neuroautoimmunity: pathogenic implications for Alzheimer's disease," Gerontology 43:79-94	
	C105	Sotgiu et al., 1998, "Genetic susceptibility to multiple sclerosis in Sardinians: an immunological study," Acta Neurol. Scand. 98(5):314-317	
	C106	Spero et al., 1980, "Plasma Exchange in Preparation of Mild Factor IX Deficient Hemophiliacs for Surgical Procedures," 19-22	
	C107	Srivastava, 2002, "Roles of heat-shock proteins in innate and adaptive immunity," Nature Rev. Immunol. 2(3); 185-194	
J	C108	Tait, 1990, "Genetic susceptibility to type I diabetes: a review," J. Autoimmun. 3 Suppl 1:3-11	
	C109	Urbaniak and Robinson, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ 300(6725):662-665	
	C110	Warshawsky et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054	
	C111	Weiner et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-1033	
	C112	Wong et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11," Clin. Exp. Immunol. 83(1):69-73	
	C113	Yamauchi et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo controlled, double blind study," Mycoses 43(5):197-202	
	C114	Zimecki et al., 1998, "Immunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken orally by healthy individuals," Arch. Immunol. Ther. Exp. (Warsz) 46(4):231-240	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYJD-1626626v1